Edition:
United Kingdom

PRA Health Sciences Inc (PRAH.OQ)

PRAH.OQ on NASDAQ Stock Exchange Global Select Market

96.81USD
6:41pm GMT
Change (% chg)

$-2.91 (-2.92%)
Prev Close
$99.72
Open
$100.11
Day's High
$100.11
Day's Low
$96.73
Volume
74,072
Avg. Vol
188,185
52-wk High
$121.98
52-wk Low
$79.49

Latest Key Developments (Source: Significant Developments)

PRA Health Sciences Says Unit Entered First Amendment, Second Joinder Agreement To Credit Agreement
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Pra Health Sciences Inc ::PRA HEALTH SCIENCES SAYS ON DEC 28, UNIT ENTERED FIRST AMENDMENT, SECOND JOINDER AGREEMENT TO CREDIT AGREEMENT DATED DEC 6, 2016‍​ - SEC FILING.PRA HEALTH SCIENCES - PURSUANT TO AMENDMENT, CREDIT AGREEMENT AMENDED TO PROVIDE NEW TRANCHE OF TERM LOANS IN AGGREGATE PRINCIPAL AMOUNT OF $601.6 MILLION.PRA HEALTH SCIENCES INC - ‍PURSUANT TO AMENDMENT, PRA RECEIVED NEW REVOLVING CREDIT COMMITMENTS IN AGGREGATE PRINCIPAL AMOUNT OF $10O MILLION.  Full Article

PRA Health Sciences reports Q3 adjusted earnings per share $0.88
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - PRA Health Sciences Inc :PRA Health Sciences, Inc reports third quarter 2017 results and updates full year 2017 guidance.Q3 adjusted earnings per share $0.88.Q3 GAAP earnings per share $0.73.Q3 earnings per share view $0.85 -- Thomson Reuters I/B/E/S.PRA Health Sciences Inc says ‍updating full year 2017 service revenue guidance to between $1.914 billion and $1.926 billion​.PRA Health Sciences Inc sees ‍full year 2017 GAAP net income per diluted share to between $2.31 and $2.38​.PRA Health Sciences Inc sees ‍full year 2017 adjusted net income per diluted share to between $3.28 and $3.35​.FY2017 earnings per share view $3.20, revenue view $1.91 billion -- Thomson Reuters I/B/E/S.PRA Health Sciences Inc qtrly ‍total revenue $582 million versus $453.3 million.  Full Article

Takeda Pharmaceutical says PRA Health Sciences and Takeda Partnership Expands to Japan
Wednesday, 15 Feb 2017 

Takeda Pharmaceutical Co Ltd <4502.T>: Says PRA Health Sciences Inc and Takeda Pharmaceutical Company Limited have agreed to a new partnership to expand their global relationship initially disclosed in September 2016 to include Japan . Says Takeda and PRA will establish a joint venture, each holding 50 percent of the share respectively, to provide clinical trial delivery and pharmacovigilance services as a strategic partner of Takeda in Japan. .Says Takeda also will transfer all of the shares of Takeda Pharmaceutical Data Services (TDS), a wholly-owned subsidiary of Takeda, to PRA.  Full Article